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Summary
Recombinant human interleukin 1 receptor antagonist (ILlra) and 35175, a neutralizing monoclonal
antibody (mAb) to the type I mouse IIA receptor, were examined for their ability to bind to
IIA receptors (IIARs) on various types of mouse cells and to block immune and inflammatory
responses to IIA in vitro and in mice. Ilrlra competed for binding of 1251-II Jct to type I IIAR
present on EL4 thymoma cells, 3T3 fibroblasts, hepatocytes, and Chinese hamster ovary cells
expressing recombinant mouse type I IIr1R. The ICso values for Ilr1ra binding (ranging from
2 to 4 ng/ml) were similar to those of IIAce. In contrast, I1rlra bound with very low affinity
(IC5o values ranging from 10 to 200 Wg/ml) to cells expressing type II IIAR, i.e., 70Z/3 pre-B
cell line and polymorphonuclear leukocytes (PMN) derived from bone marrow and acute
inflammatory exudates. The mAb 351`5 bound specifically to type I IIr1R; no inhibition of 12s1-
IIr1a binding to cells having type II HAR was observed with very high concentrations ofantibody.
While neither Ilslra nor 351`5 had intrinsic activity in bioassays using T helper D10.G4.1 cells
and mouse thymocytes, both agents blocked the ability of IIA to stimulate proliferation of these
cells. The effects ofIlrlra and 35175 on acute inflammatory responses in mice were also evaluated.
IIrlra and 35175 blocked the local accumulation of PMN after intraperitoneal injection ofrIIrlcx.
The response to IIA was inhibited when IIJ1ra or 35135 was administered simultaneously with
or before administration ofID1. IIAra and 35175 also blocked PMN accumulation after intraperitoneal
injection of lipopolysaccharide or proteose peptone, suggesting IDI is important in mediating
responses to these agents. In addition, I1r1ra and 35175 significantly blocked the ability of IIA
to stimulate egress of PMN from bone marrow, to induce a transient neutrophilia, and to elevate
serum levels of hepatic acute phase proteins, IIr6, and corticosterone. Thus, IIr1ra and 35175
competitively inhibit the binding of1Trl to the IIr1R on certain cell types. These two IIrl receptor
antagonists act to inhibit biological responses induced by IIA and other inflammatory agents.
T
he 1IA proteins, IIrlot and IIAO, are implicated in nu-
merous physiological and pathological host responses to
trauma, stress, and infection (1). Many of the actions of IIA
are pro-inflammatory and include the ability ofIIr1 to stimulate
prostaglandin E2 (PGE2)1 synthesis (2, 3), collagenase release
(2), bone resorption (4), and PMN accumulation (5-7), and
1 Abbreviations used in this paper. APP, acute phase protein; CHO, Chinese
hamsterovary; C3, complement component3;11,1ra, interleukin 1 receptor
antagonist; PEC, peritoneal exudate cell; PGE2, prostaglandin E2; SAP,
serum amyloid P.
to induce fever (8) and stimulate the acute phase response
(9). Thus, these responses create the potential for significant
IIA-mediated pathology in a number of disease states.
Recently, a humanmonocyte-derived IIrl inhibitor, desig-
nated IIA receptor antagonist (IIrlra), has been identified.
The cDNA encoding IlAra has been cloned and rILlra pro-
tein has been produced in Escherichia coli (10-12). The rIIrlra
binds to the IIr1R on E14 thymoma cells (10) and blocks
several IIrl-stimulated responses in vitro, including: (a)
PGE2 release by fibroblasts (10), synovial cells, and chondro-
cytes (13); (b) thymocyte proliferation (12, 13); (c) collagenase
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ence to endothelial cells (12, 14).
A rat mAb, 35F5, to the I1AR on mouseEIr4 thymoma
cells has recently been described (15) . Antibody 35F5 was
shown in initial studies to block the binding of 1251-ILrl to
IIAR on mouse T cells and fibroblasts (15) and to diminish
host responsesto IIrl and otherinflammatory stimuli in vivo
(16-18).
Recent studieshave shownthat at leasttwo types ofIIr1R
are differentially expressed on the surface of certain types o£
murine cells andcell lines (15, 19). The type I (T cell, fibro-
blast) receptor, but not to the type II (B cell, macrophage)
receptor, appears to selectively bind IIL1ra (10). Similarly, 35F5
binds solely to the type I IIAR but not the type II IIAR
(15). Thebindingof11r1ra or 35F5 competitivelyantagonizes
the bindingofradiolabeled Ur1(10,15). In thestudies reported
here, we have extended the observations ofearlier reportson
the in vitro activity of IIr1ra and 35F5 . In addition, to fur-
ther our understanding of thebiology and pathophysiology
of IDl, the effect of these IIs1 inhibitors on the induction




C57BL/6 and C3H/HeJ female mice, 6-8 wk of age,
were obtained from TheJackson Laboratory, BarHarbor, ME. Mice
were maintained in sterilized cages with filter tops andautoclaved
food, water, and bedding. Mice were routinely acclimated for at
least 1 wk before use.
Reagents.
￿
HumanrIIr1ra was obtained from Drs. R. Thompson
and R. Hageman, Synergen, Inc., Boulder, CO. Human rILlca
and rIL10, with specific activities of -3 x 108 U/mg, as deter-
mined in the D10.G4.1 cell proliferation assay, were provided by
Dr. S. Roy, Hoffmann-LaRoche Inc. Diluent vehicle for in vivo
studies was sterile Dulbecco's Cal*- and Mgt*-free PBS (Gibco
Laboratories, Grand Island, NY). The 11,1 used in these experi-
ments was shown by Limulus amebocyte lysate assay (Associates
of Cape Cod, WoodsHole, MA) to contain <0.2 ng endotoxin/mg
11,1. The vehicle contained <0.2 ng endotoxin per 0.1 ml. Pro-
teosepeptone(Difco Laboratories, Detroit, MI)was dissolved (3%
[wt/vol]) in endotoxin-screened water(Gibco Laboratories), passed
througha0.45-gM filter,and stored at 4°Cuntiluse. LPS (E. coli,
strain 026:136) andapurified normal rat IgG preparation were ob-
tained from SigmaChemical Co., St. Louis, MO. Purified rat35F5
mAb (15) was obtained from Drs. R. Chizzonite and A. Stern,
Hoffmann-LaRoche Inc.
Peritoneal Exudate Cells andBone Marrow Cells.
￿
Peritoneal exu-
date cells (PEC) were collected after cervical dislocation of mice
by injecting4ml serum-free RPMI 1640 (Gibco Laboratories)into
the peritoneal cavity. After vigorous massage of the abdomen, an
aliquot of the medium (33 ml) was withdrawn and the cell con-
centration was determined on acell counter (Coulter Electronics,
Hialeah, FL). Cytocentrifuge (Shandon,Inc., Pittsburgh, PA)smears
of PEC were stained with Wright's stain for differential counts.
Total of numbers of PMN accumulating in the peritoneal cavity
were calculated by multiplying total PECby thepercentPMN(de-
termined from differential counts).
To determinethe effects of 11,1 administration on bone marrow
PMN numbers, bone marrow was harvested from both femurs by
flushing with HBSS. A single cell suspension was prepared by gently
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passingthe bone marrow through 18- and then 21-gauge needles.
Totalnucleatedbone marrow cells were determined on acell counter
(Coulter Electronics).Differentialcounts ofbone marrow cells were
performed on Wright's-stained cytocentrifuge smears. The per-
centageofmaturePMN (nobands, metamyelocytes, or myelocytes)
was used forcalculations since preliminary studies showed that in-
jection of 11A (at the doses used) resulted in an increase of only
mature PMN in the peripheral blood (data not shown). Bone
marrow cells for binding assays were prepared as described below.
Binding Assays.
￿
Human rIL1a was radiolabeled with Na1asI
usingEnzymobeads reagent (Bio-Rad Laboratories, Richmond, CA)
as described (20). Murine E1,4 thymomacells (T19-181; American
Type Culture Collection, Rockville, MD) were cultured andmem-
brane fractions prepared as described(20). Binding experiments were
conducted with E1,4 membranes as described previously (20).
Briefly, the I1,1ra, 35F5, or IIr1 proteins (concentrations ranging
from 0.01 ng/ml to 6.7 mg/ml as indicated) were pre-incubated
with E1,4 membranes for 30 min at 37°C. Radiolabeled 11,1a
(30,000 cpm/ml; 20 pM final concentration) was added and the
incubation continued for 1 h at 37°C. The assay was terminated
by filtration and bound 1211-IILla was determined by use of a
gamma counter. Murine 3T3 fibroblast cell line (American Type
Culture Collection) was cultured, and binding experiments were
performedwith monolayercultures ofcells as described (21). Briefly,
confluent, adherent 3T3 cells were incubated with the unlabeled
competitor and 1151-ILla (20,000 cpm/ml, finalconcentration) for
3 h at 4°C. Thecellswere washed, detached with SDS-containing
buffer, and bound 1211-I1,1a was determined.
Chinese hamster ovary (CHO) DHFR- cells, transfected with
acDNA (providedby Dr. U. Gubler, Hoffmann-LaRoche Inc.) en-
coding the mouse type I ILiR and amplified in the presence of
methotrexate, express -6,000 mouse IL1R/cell (22). Confluent
cultures of transfected CHO cells in 24-well tissue culture plates
(Costar, Cambridge, MA) were incubatedwith competingligand
in thepresence of 1211_IIAa for 3 h at 4°C. Bound "11_ILlca was
determined essentially as described for the 3T3 cell line above.
Membranes were prepared from livers obtained from normal
C57BL/6 mice. Individual livers were excised, minced with scis-
sors, and homogenized in 25 ml buffer A (10 mM Tris-HCl [pH
7.2], 1 mM EDTA, 1 tag/ml PMSF) in a Polytron homogenizer
(Brinkman, Westbury NY). The homogenate was passed through
two layers of cheesecloth and twice clarified by centrifugation at
450gfor 10 min. Crudemembranes were collectedfrom theclarified
supernatant by centrifugation at 39,000 g for 30 min. The mem-
brane pellets were resuspended in buffer A and homogenized in
a glass-glass Dounce homogenizer. Aliquots of membranes were
stored at -80°C. Binding assays with liver membranes were per-
formed as described above for EL4 cell membranes.
The70Z/3pre-B lymphocyte cell line (American Type Culture
Collection) was maintained as described (15). Elicited peritoneal
exudatecellswere collectedby peritoneal lavage from mice injected
with proteose peptone (7). Femoral bone marrow cells were ob-
tained from mice treated 5 dearlier with 150mg/kg cyclophospha-
mide followed by four daily subcutaneous injections of IM (10
ltg/kg). Such bone marrow cells were >50% late-stage granulo-
cytes (metamyelocytes, bands, mature neutrophils) by morpholog-
ical criteria (23). Binding assays with 70Z/3, peritoneal exudate
cells, andbone marrow cellswere performedin 12 x 75-mm poly-
propylene tubes as described (7, 15). Cells were incubated with
ILlra, 35F5, or IIA proteins (concentrations ranging from 0.01
ng/ml to 6.7 mg/ml) in the presence of 1211_ILrlca for 3 h at 37°C,
and bound "11_ILla was determined by centrifugation over oil.
Hematology.
￿
Peripheral whitebloodcells (WBC)were enumer-ated on a cell counter (Coulter Electronics) . Differential WBC
counts were performed on Wright's-stained smears . AbsolutePMN
numbers were calculated by multiplying the total WBC by the
percent PMN obtained from differential counts.
Acute Phase Protein Determinations .
￿
Concentrations for serum
arnyloid P and complement component 3 (C3) were determined
by the "rocket" immunoelectrophoresis method of Laurell (24) .
Specific antisera and antigen standards were obtained from Calbio-
chem-Behring Corp., La Jolla, CA, and Organon Teknika Corp.,
West Chester, PA.
Serum Corticosterone Assay .
￿
Mice were quickly (5 s) anesthe-
tized with C02 and bled from the retro-orbital plexus. Blood ob-
tained during the first 15 s was allowed to clot at room tempera-
ture and serum was assayed for corticosterone with a commercial
RIA kit (ICN Biomedicals, Inc ., Costa Mesa, CA) .
IL6 Bioassay .
￿
Serum levels of IL6 were determined using a
modification of the B9 hybridoma cell assay described previously
(25) . Cells were treated with twofold serial dilutions of the test
sera in 96-well microtiter plates. After a 3-d incubation at 37°C
in a humidified atmosphere of 5% C02 and 95% air, the wells
were pulsed with 0.5 ACi of ['H]TdR and incubated for an addi-
tional 18 h . The cells were then harvested onto glass fiber filters
and the level of ['H]TdR incorporation was determined using a
liquid scintillation counter. 11,6 units are defined as the inverse of
the serum dilution that produces half-maximal ['H]TdR incorpo-
ration compared with a reference standard .
D10G4 .1 Assay .
￿
MouseT helper D10.G4 .1 cells (American Type
Culture Collection) were originally described by Kaye et al . (26) .
Cultures (2 x 10' D10.G4 .1 cells suspended in RPMI 1540 con-
taining 5% FCS, 5 x 10-5M 2-ME, 814g/ml gentamicin, 2 mM
L-glutamine, and 2.5 wg/ml Con A) were established in 96-well
flat-bottomed tissue culture plates. ILira or 351`5 was added to
triplicate cultures 1 h before the addition of IIAci or ILls . The
plates were incubated, and incorporation of ['H]TdR was deter-
mined as described above for the IIA assay.
Thymocyte Proliferation Assay .
￿
C3H/Hej thymorytes (1.5 x
106 ) in RPMI 1640 containing 5% FCS, 2.5 x 10-5 M 2-ME,
8 ug/ml gentamicin, and 6 wg/ml PHA were added to 96-well
microtiter plates. ILira or 351`5 was added to triplicate cultures
1 h before the addition of ILla or ILlO . The plates were incubated,




Data are presented as the mean ± SD of
three to five mice per group. The differences between treatment
groups were analyzed by Student's t test (27) and were considered
statistically significant at p < 0.05 .
Results




ined for its ability to inhibit binding of 1251-IL1cY to a
number of cells and cell lines (Table 1) . The IC5o values for
ILira binding (i.e., concentration of competitor inhibiting
binding of 1251_IL1a by 50%) ranged from 2 to 4 ng/ml in
experiments performed with mouse E14 thymoma, 3T3
fibroblast, and CHO cells expressing recombinant mouse type
I IL1R . These IC5o values for ILira were similar to those
obtained for ILla and ILlf with these same cell types .
The binding of these three ligands to additional cell types
933
￿
McIntyre et al .
Table 1 .
￿
Inhibition of Binding of '25LIL-la to IL-1R on Cells
and Cell Lines by IL-1 Proteins, IL-1 ra, and 351`5 antibody
Competitive inhibition binding experiments were performed with 125I-
IL-la and indicated cells and cell lines as described in Materials and
Methods . IC50 values were determined from graphed binding data of
complete competitive inhibition dose-response curves for each indicated
competitor .
Assays performed with membrane preparations .
t Assays performed with intact cells .
was examined further. Both ILla and 1140bound with high
affinity to 111R present on the mouse 70Z/3 cell and to pro-
tease peptone-elicited mouse peritoneal neutrophils and to
granulocytes and granulocyte progenitors obtained from mouse
bonemarrow . In contrast, ILira bound with very low affinity
to these cell types (IC5o values ranging from 10 to 200
1~g/ml) . Inhibition of binding by the IL1 proteins and ILira
was specific since concentrations ofIL2 up to 1 mg/ml were
found to have no effect on the binding of 1251-ILla to any
of the cell types (data not shown) .
The anti-ILIR mAb 351`5 was examined for its ability to
block the binding of 1251-IL1a to IL1R (Table 1) . Antibody
351`5 inhibited the binding of IL1 to the type I IL1R on
T cells, fibroblasts, hepatocytes, and CHO cells expressing
type I mouse IL1R with an affinity comparable with that
of ILira, taking into consideration the -10-fold difference
in molecular weight ofthe two inhibitors . In contrast to ILira,
however, antibody 351`5 is highly specific for type I IL1R,
as concentrations of 351`5 up to 6.7 mg/ml failed to inhibit
the binding of IIA to IL1R on 70Z/3 cells and inflamma-
tory and bone marrow-derived PMN (Table 1) . This finding
was corroborated by studies in which no binding of radiola-
beled 1251-351`5 to IL1R on these cells was detected (data not
shown) .
Effect of ILira and 351`5 on III-stimulated T Cell Re-
sponses. ILira inhibited, in a dose-dependent manner, the
co-mitogenic effect of ILl on D10.G4 .1 cells and mouse
thymocytes (Table 2) . A 1,000-fold molar excess ofILira over
IIA was needed to completely block the response to IL1a
in bioassays. However, the inhibition by ILira was specific
since higher concentrations of ILl could overcome the in-
Cell or cell line (type)
inhibition of binding of "'I-IL-la
IL-1a IL-10 IL-Ira 351`5
IC5o, ng/ml
EL-4 (thymoma)' 2.0 10 2.0 20
3T3 (fibroblast)t 1 .0 2 .0 4.0 ND
CHO cells w/ rIL-1Rt 1 .5 10 2.0 20
Hepatocytes" 2.0 ND 2.0 20
PMN from :
Peritoneal cavityt 10 ND 1 x 105 >6.7 x 106
Bone marrowt 3.0 ND 2 x 105 >6.7 x 106
70Z/3 (pre-B cell)t 14 ND 1 x 10' >6.7 x 106Table 2.
￿
Inhibition of IL-1-stimulated DIO.G4.1 and
Thymocyte Proliferation by IL-Ira and 35175
D10.G4.1 cells or C3H/HeJ thymocytes were preincubated with the in-
dicated concentrations of IL-lra or 35F5 for 60 min at 37°C before addi-
tion of IL-1 as described in Materials and Methods .
hibitory effect of II,lra . The inhibitory effect of IL1ra on
ILlß-induced proliferation was similar to that seen with Mot
(data not shown) .
mAb 35175 was also tested in these in vitro assays . Anti-
body 35175 demonstrated a dose-dependent inhibition of
proliferation of both D10.G4.1 cells and thymocytes at low
concentrations of IL1 (Table 2) . These effects of 35175 were
reversed at higher concentrations of IL1.
In Vivo Studies with ILira and 35175
Inhibition of ILI-stimulated Induction ofIL6 by ILlra.
￿
IL
Ira inhibited theinduction of IL6by II loi in adose-dependent
manner when IIrlra was injected simultaneously with IIA
(Table 3) . Theinhibition was maximal when >100-fold excess
of ILlra over IL1 was administered . Furthermore, inhibi-
tion wasobservedwhen 10mg/kgofIIArawas administered
simultaneously with or 1-2 h before 10 Wg/kg of IIA; no
inhibition was seen when IIL1ra was given 4 h before IL1
(Fig . 1) . Administration of 35175 to mice also blocked induc-
tion of IL6 by IL1 (data not shown), confirming previous
studies (18) .
Inhibition of Acute Phase Protein Synthesis by ILlra and
35175.
￿
The effect of IL1ra on ILI-stimulated increases in
Table 3.
￿
IL-Ira Inhibits IL-1-induced Elevation ofIL-6 Levels in
Serum in a Dose-dependent manner
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C57BL/6 mice (four/group) were injected subcutaneously with the in-
dicated dose ofIL-lra together with 10 Kg/kg IL-1 .The mice were bled
3 h later and the levels of serum IL-6 were determined .
p < 0.05 compared with IL-1 alone .
the hepatic acutephase proteins (APP), serum amyloidP(SAP)
and complement component 3 (C3), was examined.A single
injection of IIAra given simultaneously with or 15 min be-
fore IIA significantly attenuated the increases in SAP andC3
observed 24 h after IIA injection (Fig . 2) . When ILlra was
injected 15 min after IL 1, the IL-1-stimulated levels ofSAP
and C3 were not significantly reduced. Thus, II.-Ira max-
imally inhibited IL-1-stimulated APP synthesis when given
simultaneously with ILl .
Significant reductions in IL-1-stimulated SAP levels were
also observed upon administration of 35F5 antibody to mice.
Increases in serumSAP levels were blocked in adose-dependent
manner by 35175 (Table 4, Exp. 1) . Theinhibition of the 11,1-
stimulated increase in SAPwas observed when 35175 was ad-
ministered before,but not after, ILl (Table 4, Exp. 2) . Anti-
Figure 1 .
￿
Effect of time of IIArainjection on ability to block induction
of serum 11,6 by IL-a . C57BL/6 mice (four/group) were injected with
ILlra (5 mg/kg, sc.) at various times relative to injection ofIILla (5 ug/kg,
sx .) . Mice were bled 3 h after ILl injection and serum 11,6 levels were
determined. Control (PBS-injected) mice had no detectable (<20 U/ml)
IL-6 (data not shown) . 'p<0.05 compared with mice receiving no IIArá .






ng/ml cpm x 10-3
1 0 0 3 87
0.12 0 49 220
0.12 1 .2 39 143
0.12 12 20 100
0.12 120 2 60
12 0 52 225
12 120 51 173
IL-la 35175 D10.G4.1 Thymocytes
ng/ml cpm x 10 -3
2 0 0 7 19
0.12 0 60 38
0.12 10 46 12
0.12 100 22 7
0.12 1,000 5 12
12 0 61 60






10 0 3,850 ± 1,050
10 1 3,350 ± 1,400
10 10 1,950 ± 850'
10 100 1,200 ± 550'
10 1,000 300 ± 150`Figure 2 .
￿
Inhibition of ILl-stimulated acute phase protein synthesisby
IITlra. C57BL/6 mice (three/group) were injected with PBS or IIA (5
Pg/kg, s.c.) . Additional groups of mice were injected with IIA (5 Wg/kg,
s.c .) and IIAra (10 mg/kg, ix.) at various times relative to the injection
of IIA. Mice were bled 24 h later and concentrations of serum SAP and
C3 were determined by immunoelectrophoresis as described in Materials
and Methods. Reductions in SAP and C3 levels in mice receiving I1rlra
at -15 or 0 min were statistically significant (p < 0.02) compared with
levels in mice receiving II.1 alone.
body 351`5 has also been shown to modulate SAP levels in
mice during inflammation induced by other agents (17) .
Inhibition ofIA-stimulated Adrenal Glucocorticoid Release by
351`5.
￿
Antibody 351`5 was tested for its ability to block in-
creases in serum corticosterone induced by IL-1 (Fig. 3) . Com-
Table 4 .
￿
Inhibition In Vivo ofIL-1-stimulated Acute Phase Protein
Synthesis by the anti-IL-IR mAb, 351`5
In exp . 1, C57BL/6 mice (four/group) were injected subcutaneously with
various doses of 351`5 antibody 4 h before subcutaneous injection of IL-la
(5.0 pg/kg) . Mice were bled 24 h after IL-1 injection for SAP determi-
nations . In exp . 2, C57BL/6 mice (four/group) were injected subcutane-
ously with 351`5 (10 mg/kg) at the indicated times before or after
subcutaneous injection of IL-la (5.0,ug/kg) . Mice were bled 24 h after
IL-1 injection for SAP determinations .
p < 0.05 compared with IL-1 .
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Figure 3.
￿
Inhibition of corticosterone release by 351`5 . C57BL/6 mice
(four/group) were injected intravenously with 351`5 (5 mg/kg) 30 min
before intraperitoneal injection of I1A (5,ug/kg) or PBS, and serum samples
were obtained 2 h later. Serum corticosterone levels were determined by
RIA as described in Materials and Methods. ' p < 0.02 compared with
ILl alone.
pared with PBS-injected control mice, mice injected with 5
ug/kg ofIIA alone showed an increase in serum corticosterone
of N10-fold . This IIA-stimulated increase was significantly
(p < 0.02) blocked in mice treated with 5 mg/kg of 351`5 .
Injection of 35175 alone did not alter serum corticosterone.
Injection of mice with ILlra also blocked IL-1-stimulated in-
creases in serum corticosterone (data not shown), in agree-
ment with an earlier report (12) .
Suppression by ILlra and 351`5 of ILl-induced Neutrophilia
and Release ofPMNfrom Bone Marrow . IIrlra and 351`5 were
tested for their ability to block IL1-induced neutrophilia in
mice. Treatment ofmice with 10mg/kg of IL1ra eliminated
both the relative and absolute increases in peripheral blood
PMN in response to 5 lAg/kg of IL1(Table 5, Exp. 1) . Injec-
tion of IL1ra alone caused no change in peripheral blood leu-
kocyte numbers (data not shown) . In addition to stimulating
an increase in numbers ofPMN in the blood, injection of
II,1 induced a reciprocal decline in numbers ofPMN in the
bone marrow. This depletion of bone marrow PMN was
largely blocked by treatment with IIrlra . Treatment of mice
with 10 mg/kg of 351`5, but not a control preparation of
purified rat IgG, blocked both relative and absolute neu-
trophilia induced by injection of IL-1 (Table 5, Exp. 2) .
Inhibition ofIL1-inducedPMN Accumulation by ILlra .
￿
To
study the effect of ILlra on IIA-induced PMN accumula-
tion, mice were treated with IILlra at various times relative
to the injection of 5.0 ng/kg of ILlot . The data in Fig. 4
demonstrate that IL1ra must be administered at the time of,
or shortly before, ILA injection in order to inhibit PMN ac-
cumulation in response to IIA . Thus, accumulation ofPMN
in response to IIA was significantly inhibited in mice treated
with IIAra at the same time as or 10 min before IL1 injec-
tion . The inhibitory effects of ILlra were markedly dimin-
ished when ILlra was administered 30 min before IL1. Fur-
thermore, ILlra was unable to block the PMN influx when
given 10 min after IL1 . When tested over a range of doses
(50 pg/kg to 5 mg/kg), injection ofIIr1ra alone did not elicit
Exp . Treatment SAP
ag/ml
1 PBS 12 .3 ± 3.5
IL-Ia 75 .3 ± 14.2
35F5 (0.1 mg/kg) + IL-1a 55 .8 ± 4.3"
35F5 (0.5 mg/kg) + IL-lca 49.8 ± 1.5'
351`5 (2.5 mg/kg) + IL-1a 47.5 ± 6.1'
35F5 (10.0 mg/kg) + IL-1a 38.3 ± 1.5'
2 PBS 6.5 ± 1.3
IL-la 59.3 ± 8.0
35F5 (-4 h) + IL-la 32.0 ± 2.7"
35F5 (-1 h) + IL-la 41 .5 ± 6.9"
35F5 (+ 1 h) + IL-la 58.0 ± 8.8
35F5 (+4 h) + IL-la 51.3 ± 5 .2In Exp . 1, mice (three/group) were injected intraperitoneally with 0.1 ml PBS (control), 0.1 ml PBS containing either 0.5 !cg/kg of IL-1a or 0.5
pg/kg of IL-la, plus 5 mg/kg of IL-lra . In Exp . 2, mice (five/group) were injected subcutaneously with 10 mg/kg of purified rat IgG or 35F5
antibody 18 h before intraperitoneal injection with 5 ííg/kg of IL-1a . Mice were bled 4 h after IL-1 injection and absolute numbers and percentages
ofPMN in peripheral blood and in femoral bone marrow were determined.
p < 0.05 compared with control .
tp < 0.05 compared with IL-la alone .
PMN influx (data not shown) . Other routes of administra-
tion for I1r1ra were also highly effective at blocking localized
peritoneal responses to IIrl. Parenteral (subcutaneous or in-
travenous) administration of IIArajust before intraperitoneal
injection of IIA also blocked accumulation of PMN (data
not shown) .
Inhibition ofLPS- and Proteose Peptone-inducedPMN Accumu-
lation by II lra and 35F5. The effects of I1rlra and 35F5 on
acute inflammatory responses to LPS and proteose peptone
were studied . Mice were injected with IIAra or 35F5 and
then injected withLPS (5 wg/kg) or sterile proteose peptone
(1.0 ml, 3% solution) . As shown in Fig. 5, both IIAra and
35F5 significantly inhibited PMN influx induced by both of
these agents, suggesting that IIA mediates this PMN response
Figure 4 .
￿
Time ofIlAra injection affects ability to inhibitPMN influx .
Mice (three/group) were injected intraperitoneally with either PBS (con-
trol) or ILl (5 ng/kg, all other groups) . Individual groups were injected
intraperitoneally with I1Jlra (5 mg/kg) at various times relative to IIA
injection as shown . PEC were collected from all mice 4h after IIA injec-
tion and total PMNdetermined . *p < 0.005 compared with IIrl alone.
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to LPS and proteose peptone. In repeated experiments, IIr1ra
and 35F5, even at high dose (50 mg/kg), only partially blocked
(55-80%) the response to LPS and proteose peptone, whereas
the PMN influx in response to IIrl can often be virtually
eliminated with l1rlra (McIntyre et al ., unpublished obser-
vations) . These findings suggest that factors in addition to
IIrl may be involved in regulating PMN accumulation in
vivo in response to LPS and proteose peptone.
Figure 5 .
￿
Inhibition byIIAra ofperitoneal accumulation ofPMN stimu-
lated by LPS or proteose peptone . Mice (four/group) were injected with
Ilrlra (5 mg/kg, i.v. ; and 5 mg/kg, i.p .) or 35F5 (5 mg/kg, i.p.) at 10
min beforeintraperitoneal injection ofLPS (5 ííg/kg) . Mice were injected
with ILlra (20 mg/kg, i.p.) or 35F5 (5 mg/kg, i.p.) at 10 min before
intraperitoneal injection of1.0 ml proteose peptone(3% lwt/volt) . Total
PMN in the peritoneal cavities were determined at 4h . The data are ex-
pressed as a percent of thePMN response in the absence ofinhibitor (LPS
alone: 1.52 t 0.49 x 106 PMN/mouse ; proteose peptone alone: 1.84 t
0.53 x 106 PMN/mouse) . Values for mice treated with either ILlra or
35F5 were significantly lower than for mice receiving LPS or proteose
peptone alone (p < 0.05) .
Table 5 . Inhibition of IL-1-induced Neutrophilia and Release ofPMNfrom Bone Marrow by IL-Ira and 35F5








1 Control 14.0 ± 3.0 1 .1 ± 0.4 12.0 ± 1.7 4.0 ± 0.8
IL-la 35.7 ± 1.5' 2 .1 ± 0.3' 4.2 ± 1 .3' 1 .2 ± 0.6`
IL-lra + IL-la 12.3 ± 3.5t 0.8 ± 0.2t 8.0 ± 0.9t 2 .6 ± 0.5t
2 Control 6.2 t 1.8 0.5 ± 0.1 ND ND
IL-la 27.2 ± 6.4" 1.8 ± 0.4" ND ND
IgG + IL-la 29.4 ± 4.7' 1 .8 ± 0.2' ND ND
35F5 + IL-la 10.0 ± 3.4t 0.8 ± 0.2t ND NDDiscussion
A previous study by Hannum et al. (10) showed that II,
lra binds to IIAR present on E14 thymoma cells with an
affinity approximately equal to that for human IIA0 . Our
experiments show that IIrlra also inhibits binding of t25I-
Ilrla to membranes prepared from El4 cells with an ICso
of x+2.0 ng/ml . This value is comparable with those obtained
for IIrla and Ills (2.0 and 10.0 ng/ml, respectively) . In
addition, Illra bound with high affinity to theIl1R present
on the3T3 fibroblast cell line and to mouse rI11R expressed
byCHO cells . The I11R present on EIr4 and 3T3 cells is
identical to that which has been cloned and expressed in CHO
cells and has been tentatively designated as the T cell/fibro-
blast, or type I, IIr1R (15, 19) . A second type ofIIAR, desig-
nated the B cell/macrophage or type II ID1R, is present on
murine macrophage and B cell lines and onPMN andPMN
progenitors (15, 19) . Studies byHannum et al . (10) and Carter
et al. (12) suggest that IIrIra binds to the type I IIAR but
not to the type II IIAR . In this report, high concentrations
of I11ra were evaluated in competitive inhibition experiments
using 70Z/3 pre-B cells, proteose peptone-elicited peritoneal
exudate cells, and bone marrow cells. Our results show that
IIrlra blocks binding ofradiolabeled IIrlot to the type II mouse
I11R at very high concentrations. An ICso of 30 lAg/ml was
obtained for 70Z/3 cells . A concentration of 200 lAg/ml of
I1r1ra was found to inhibit binding of IIrla to proteose pep-
tone-elicited peritoneal exudate cells or bone marrow cells
by 50% . Previous work has shown that PMN in the perito-
neal exudate cell population (7) and granulocytes and granu-
locyte progenitors in bonemarrow (K.P. Parker, K.W. McIn-
tyre, and P.L . Kilian, unpublished observations) are the cells
expressing IDIR . We conclude from these binding experi-
ments that IIx1ra binds with high affinity to the type I IIAR
and with a greatly reduced affinity to the type II I11R .
The receptor binding experiments with 35175 confirm and
extend previous observations (15) that this antibody specifically
recognizes the type I IIAR and shows no detectable inhibi-
tory activity on type II I11R even at high concentrations
(Table 1) . This finding has important implications for the
interpretation ofthe in vivo experiments with IIrlra reported
here. In the responses examined, a large molar excess of Il
1ra over Ill (102 - to 105-fold) is often necessary to achieve
significant inhibition . This raises the question of whether
the IIAra at these high doses may bind to type II 111R in
vivo, thereby inhibiting Ill-induced responses through in-
teraction with type II IIr1R. However, this possibility is un-
likely inasmuch as the type I IIAR-specific 35175 antibody
reproduces the inhibitory activities of IIAra in vivo (and in
vitro) . These findings confirm the proposition that suppres-
sion of these Ill-stimulated responses is mediated through
interactions with the type I IIr1R .
The studies on stimulation of thymocyte and D10.G4.1
cell proliferation by Ill suggest that very few IIr1Rs need
to be occupied by Ill in order to elicit a biological response.
Proliferation ofD10.G4.1 cells is stimulated by 11,1 concen-
trations that are substantially lower than the ICso obtained
for Ill in receptor binding assays . Similar findings were




(28) and suggest that a large proportion of I11R on cells
are present as "spare receptors". Based on these findings, it
would seem likely that near saturation of IIAR with I1r1ra
would be required to achieve antagonist activity (13) . This,
in turn, probably explains why a high molar excess of IIrlra
or 35175 over IIr1 was needed to block the effects of Ill in vivo .
APP synthesis by the liver during inflammation is regu-
lated by the concerted action of multiple soluble mediators .
The presence of I11, 116, and adrenal glucocorticoids is re-
quired for maximal stimulation ofAPP synthesis by hepato-
cytes in vitro (29) . This condition is met in vivo where injec-
tion of Ill into mice stimulates increased levels of both IIr6
and glucocorticoids. However, IIAra (Fig. 1) and 35F5 (18)
prevent the induction of IL-6, and both Il1ra (12) and 35175
(Fig . 3) block corticosterone release . In addition, these type
I IIr1R antagonists block the binding of Ill to I1r1R on
liver cells (Table 1) . Thus, the combined action of the three
signals important for the stimulation of hepatic APP syn-
thesis is suppressed by Illra and 35175, resulting in inhibi-
tion of this IIr1-stimulated response (Fig. 2, Table 4) .
The appearance of PMN at sites of inflammation is the
result of a coordinated series of events . These steps may in-
clude release of PMN from bone marrow into the circula-
tion, their adherence to endothelial cells, and then their sub-
sequent migration into adjacent tissues. The release ofPMN
from bonemarrow and the subsequent neutrophilia induced
by Ill injection are suppressedby ILlra (Table 5) . However,
IIrlra failed to reduce Ill-stimulated neutrophilia in other
studies (12) using a higher dose of Ill than that used here.
That failure of IIr1ra to inhibit neutrophilia (possibly due
to an insufficient molar excess of I11ra) led to the suggestion
that the type II IIAR was mediating this response (12) . How-
ever, our current data with IIr1ra and 35175 demonstrate that
Ill-stimulated neutrophilia is indeed blocked by type I IL
1R antagonists.
Adhesion of PMN to endothelial cells is a step crucial in
PMN accumulation (30, 31). Adhesion is augmented by 11,1
through increased expression of adhesion glycoproteins on
endothelial cells (31), and I1r1ra pretreatment of endothelial
cells blocks this response (14) . Accumulation ofPMN is fur-
ther stimulated by the localized generation of factors chemo-
tactic for PMN . The PMN chemotactic factor I18 (33) is
synthesized by fibroblasts (34, 35) and endothelial cells (36)
upon exposure to ID1 . Since these cell types express type I
IIAR, I1r1ramay be able to block this response as well. Thus,
in mediating its inhibition ofPMN accumulation, Il1ramay
act at three steps in the inflammatory pathway by : (a) blocking
PMN release frombonemarrow and theresulting neutrophilia;
(b) blocking endothelial cell/PMN adhesion ; and (c) blocking
the generation of specific PMN chemotactic factors .
Our results also demonstrate that Illra and 351`5 block
PMN accumulation in response to the nonspecific stimuli LPS
and proteose peptone . This holds significance for the mecha-
nism of action ofvarious stimuli in mediating acute inflam-
matory cell infiltration. The ability of IIr1ra and 35175 to in-
hibit PMN influx after injection of proteose peptone or LPS
strongly suggests that ILA is an important participant in theseresponses. However, ILI does notappear to be the sole respon-
sible mediator since IL1ra and35F5 fail to completely block
PMN accumulation . Other factors such as complement com-
ponent fragments andleukotrienes are chemotactic forPMN,
and these factorsmaybe generatedby IL1-independent mech-
anisms after injection of proteose peptone or LPS.
In summary, our experiments show that human rIL1ra
binds with very high affinity to the type I IL1R and with
a greatly reduced affinity to type II IL1R . In contrast, 35F5











and 35F5 antibody inhibit a wide variety of ILl-stimulated
physiological responses in vivo. Both ILlra and 35F5 also
modulate responses to nonspecific inflammatory stimuli, im-
plying a role for ILI in these models . Furthermore, these
data demonstrate that the type I IL1R represents the pre-
dominant signalingpathway for many host responses attrib-
uted to ILI. Therole ofthe type II IL1R in normal or patho-
logicalconditions is unclear. Elucidation of its physiological
function awaits the identification of antagonists (or agonists)
specific for the type II IL1R .
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